Maze Therapeutics, Inc Common Stock
Yahoo Finance • 16 days ago
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT VNCE [https://www.chartmill.com/stock/quote/VNCE/profile] 113.0% VINCE H... Full story
Yahoo Finance • 16 days ago
Which stocks are moving on Thursday?
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] GAINERS TICKER CHANGE COMMENT VNCE [ht... Full story
Yahoo Finance • 16 days ago
Thursday's session: gap up and gap down stocks
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT VNCE [https://www.chartmill.com/stock/q... Full story
Yahoo Finance • 16 days ago
Discover the top movers in Thursday's pre-market session.
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT YYGH [https://www.chartmill... Full story
Yahoo Finance • 16 days ago
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic disea... Full story
Yahoo Finance • 16 days ago
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD... Full story
Yahoo Finance • 25 days ago
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic disea... Full story
Yahoo Finance • 2 months ago
Maze Therapeutics Inc (NASDAQ:MAZE) Reports Narrower Q2 2025 Loss, Extends Cash Runway to 2027
MAZE THERAPEUTICS INC (NASDAQ:MAZE [https://www.chartmill.com/stock/quote/MAZE]) REPORTS Q2 2025 EARNINGS: NARROWER LOSS THAN EXPECTED, CASH RUNWAY EXTENDS TO 2027 Maze Therapeutics, a clinical-stage biopharmaceutical company focused on k... Full story
Yahoo Finance • 2 months ago
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling Patients with APOL1-Mediated Kidn... Full story
Yahoo Finance • 3 months ago
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardio... Full story
Yahoo Finance • 4 months ago
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiov... Full story
Yahoo Finance • 5 months ago
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiov... Full story
Yahoo Finance • 6 months ago
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in Gross Proceeds in U... Full story
Yahoo Finance • 8 months ago
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines... Full story
